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Abstract: Lanthionine (Lan), a non-proteinogenic natural amino acid, is an essential component of peptidoglycan found 
in the cell wall of Fusobacterium species. Lan and -methyllanthionine are also key constituents in lantibiotics, a prevalent 
class of peptide antibiotics. The development of those new antibacterial drugs with enhanced properties is the focus of 
recent research. Since multiple isomers of Lan are possible, a regio- and diastereoselective synthesis is challenging. This 
comprehensive review summarizes the known chemical syntheses of lanthionine from various precursors (e.g., -
chloroalanine, cystine, dehydroalanine, -iodoalanine, aziridine, serine lactone, sulfamidate) since 1941. Methods for 
preparation of unprotected, protected, orthogonally protected, and mutually orthogonally protected lanthionine with 
relevant experimental details and perspectives on their usefulness are provided. The potential of these Lan derivatives is 





The widespread use of antibiotics in human and veterinary medicine, has caused bacteria to become drug resistant. As 
reported by the World Health Organization in 2014, antibiotic resistance is now a major public health issue in the world. [1] 
To overcome this growing problem, the development of new antibacterial drugs with different mechanisms of action is a 
subject of several researches.[2] One of the three main modes of action of antibiotics concerns the synthesis of the bacterial 
cell wall.[3] This complex structure contains a reticulated macromolecule known as the peptidoglycan (PG)[4] which plays a 
structuring role in the surrounding cytoplasmic membrane.[4-5] The viability of bacteria depends on the integrity of their PG 
which protects them from osmotic lysis. The complex biosynthesis of PG implies numerous enzymes making it an attractive 
target for the development of new antibiotics.[6] In some bacterial strain such as Fusobacterium species, Lanthionine (Lan 
1, Figure 1) is an essential component of the PG, required for the crosslinking of this biological macromolecule. [7] Recently, 
lanthionine has been proposed as a human uremic toxin able to inhibit H2S release and to contribute to 
hyperhomocysteinemia in uremia.[8] Lanthionine (Lan 1), a non-proteinogenic diamino diacid, is structurally related to 
cystine 2. This monosulfide analog of 2 is composed of two alanine moieties each of R or S configuration linked on their 
-carbon by a sulfur atom (Figure 1). 
Figure 1. Lan 1 (-amino--carboxy-ethylsulfide) and (R,R)-cystine 2. 
Lan 1 and -Me-Lan are key components in lantibiotics, a class of peptide antibiotics which are promising lead compounds 
in this field of research.[4a, 9] Nisin, the most notorious member of the lantibiotic family, is used since more than fifty years 
in the food industry as a broad spectrum food preservative. Lantibiotics exhibit good antimicrobial activity against a large 
range of multidrug resistant bacteria and possess multiple unconventional modes of action which reduce the rate of 
acquired resistance. 
The lantibiotics are part of the family of the ribosomally synthesized and post-translationally modified peptides (RiPPs). 
The biochemical synthesis of Lan and -Me-Lan in peptides occurs during the post translational modification. A ribosomally 
synthesized precursor peptide (LanA) is composed of an N-terminal leader peptide attached to the core peptide where the 
modifications occur. Dehydration by phosphorylation and subsequent elimination of phosphate transform serine and 
threonine residues into dehydroalanine (Dha) and dehydrobutyrine (Dhb), respectively. The leader peptide control the 
order and direction of this enzymatic process. An ordered enzymatic cyclisation of cysteine residues with the Dha and Dhb 
followed by leader peptide removal leads to the final lanthipeptide.[9f-l, 10] 
The size and complexity of those cyclic lanthipeptides make biochemical and chemical synthesis of lantibiotic difficult. The 
more versatile chemical approach allows straightforward peptide variations leading to lantibiotics with potentially enhanced 
properties.[11] A first review on the chemical synthesis of lanthionines and related peptides was published in 2003 by 
Süssmuth et al.[12] The main chemical and enzymatic syntheses of lanthionines were reviewed by the Van der Donk 
group.[9f, h, 13] Recent chemical reviews in the field of lantibiotics and lanthionines preparation were reported in 2011 and 
2014 by Tabor.[10, 14]  
In this comprehensive review, practical synthesis of lanthionines and derivatives since 1941 as well as recent 
developments reported in their syntheses during the last decade are described. Relevant details of experimental conditions 
allowing comparisons of the different synthetic procedures are disclosed. This review concerns both unprotected and 
variously protected lanthionines. To illustrate the potential of those derivatives one recent application is also presented. 
2. Background 
Around 1925, human hair was the main material used to prepare (R,R)-cystine (2, Figure 1).[15] The process involved a 
preliminary wash of the hair with soap to remove oil and waxes. A cold aqueous Na2CO3 (1-2%) solution was also often 
used for this purpose. A 5% (w/w) yield of 2 was then obtained after heating at 100 °C with aqueous HCl (6 M) for 120 h, 
followed by neutralization and precipitation.[15] Other keratinous materials such as wool and feather were also used. 
Nevertheless, Hoffman discovered that this procedure did not lead to any cystine isolation if the preliminary wash was 
done with aqueous Na2CO3 (1%) at 100 °C.[16] In that case, after 2 h of stirring, a loss of 23.8% of the sulfur content of the 
hair was recorded. As crystallization of cystine was prevented in the last step, Hoffman assumed that its structure had 
thus been altered. 
Later, in 1941, Lan was first isolated by Horn et al. after boiling wool with aqueous Na2CO3 (2%) for 1 h.[17] This diamino 
diacid was optically inactive and was identified as the symmetrical -amino--carboxy-ethylsulfide (1, Figure 1) based on 
the evidence of elemental analysis, general properties and chemical behaviour. Compound 1 was crystallized in triangle-
like hexagonal plate in a yield of 0.5% (w/w). 
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As compound 1 was isolated from wool and contains sulfur, it was named lanthionine. Its structure was confirmed, in 1941, 
by Brown and Du Vigneaud after chemical synthesis (yield 4.2%) and comparison of optical-crystallographic data.[17-18] 
The optical inactivity of 1, crystallizing in triangle-like shape, suggested that it was the meso-isomer. During the process, 
a second compound, more soluble and differing in crystalline form, was also recovered (yield 0.5%). Those latter crystals 
presented the same composition as the meso-form and, except solubility, melting point and crystalline form, displayed the 
same chemical properties. This new derivative, crystallizing in various forms depending on the solvent used (dimorphism), 
was also optically inactive. It was concluded that this last compound was a mixture (1:1) of both enantiomers of Lan (i.e. 
dl-Lan).[19] The meso-Lan was also isolated from chicken feather (0.25%, w/w), human hair (2.5%), lactalbumin (0.25%) 
and insulin (1%).[20] A recent review by Galande et al. describes the mechanism of the base-induced desulfurization of the 
cystine residue to Lan inside small peptides (Scheme 1).[21]  
Scheme 1. Probable mechanism for the formation of Lan in peptides upon base treatment. 
The transformation involves a -elimination from cystine giving a Dha and an unstable disulfide anion.[22] Subsequent loss 
of sulfur and Michael addition of the liberated cysteine (Cys) residue on the Dha provides a Lan bridged peptide (Scheme 
1).[21-22] 
3. Chemical synthesis of unprotected lanthionine 
3.1. Generality 
As described in the previous section, Lan is a diamino diacid with a central monosulfur linked to two alanine residues each 









Figure 2. A: Stereochemical forms of Lan 1; B: the two naturally occurring diastereomers of -Me-Lan. 
Assuming a Lan synthesis from racemic starting materials, the ratio of each diastereomer would be as follows: the two 
optically active forms [(R,R)-Lan and (S,S)-Lan] contribute each for 25% and the meso-Lan for 50%. The nomenclature 
presented in Figure 2 will be used throughout this review. 
Since multiple isomers of Lan are possible, regio- and diastereoselective synthesis of protected and unprotected Lan is 
challenging. The importance of Lan stereochemistry in lantibiotics was recently demonstrated in the case of lacticin 481 
by Knerr and Van der Donk.[23] Until 2013, only meso-Lan and (2S,3S,6R)--Me-Lan (Figure 2B) stereoisomers had been 
detected in lantibiotics. However, Tang and Van der Donk recently reported the unusual (R,R)-Lan and (2R,3R,6R)--Me-
Lan configurations in cytolysin.[24] In 2014, those unusual lanthionines stereochemistries were also discovered by Lohans 
et al. in carnolysin.[25] 
In the following paragraphs different syntheses of unprotected Lan from various precursors are presented. 
3.2. Synthesis from -chloroalanine 
The first chemical synthesis of Lan 1 and its structural proof were reported, in 1941, by Brown and Du Vigneaud.[18] Lan 1 














Scheme 2. The first route to Lan 1. i) (R)-3 (250 mmol, 2.17 eq), rac-4 (115 mmol, 1 eq), KOH (33% aq, 648 mmol), 45 °C, 3 h, fractional 
crystallization, 4.2% (meso-1, 1 g). 
The reaction, occurring in a basic solution of KOH, led to a mixture of products. Indeed, Lan was contaminated with 
(R,R)-cystine 2 (from the dimerization of 3) and another compound. After sequential fractional crystallizations and 
microscopic examination, pure triangle-like crystals of Lan 1 were obtained (yield 4.2%). The physical and chemical 
properties of this compound were identical to the first form of Lan isolated from wool by Horn et al.[17] If reaction between 
rac-4 and (R)-3 proceeded without epimerization of 3, only (R,R)-Lan and meso-Lan could have been formed (Scheme 2). 
Since the triangle-like crystals (cf. 2. Background) were optically inactive, the meso-Lan (meso-1) was synthesized.[18] 
Brown and Du Vigneaud have also reported the preparation of the (R,R)-Lan diastereoisomer by reaction of (R)-5 with 
Cys (R)-3 (prepared in situ from (R,R)-cystine) in presence of aqueous KOH for 4 h (Scheme 3).[26] After successive 
neutralization, precipitation, cystine removal (NaCN) and recrystallization, (R,R)-Lan was obtained in 34% yield. Using a 
similar procedure, the (S,S)-Lan diastereoisomer was prepared from (S)-3 (previously generated in situ from (S)-BnS-Cys) 
and (S)-5 in 21% yield. An equal amount of (R,R)-Lan and (S,S)-Lan were then mixed in aqueous ammonia and acetic 
acid was added to crystallize dl-Lan (dl-1, Figure 2 and Scheme 3).[26] This method was also used to prepare a homologue 
of Lan, namely cystathionine.[27] 
Scheme 3. Diastereoselective synthesis of Lan 1. i) (R)-3 (117 mmol, 1.34 eq), (R)-5 (87 mmol, 1 eq), KOH (33% aq, 250 mmol), 45 °C to rt, 4 h, 
recrystallization (NaCN), 34%; ii) (S)-3 (71 mmol, 1 eq), (S)-5 (81 mmol, 1.15 eq), KOH (33% aq), 45 °C to rt, 4 h, recrystallization, 21%; iii) equimolar 
(R,R)-1 and (S,S)-1, NH4OH, AcOH. 
In 1979, the same procedure was used by Photaki et al. to synthesize (R,R)-Lan, in a higher yield (75%), from commercially 
available Cys (R)-3. Likewise, using (S)-5 and (R)-3, meso-Lan was obtained in 55% yield.[28] 
Moreover, the same paper also presents a synthesis of cyclolanthionine from N-CBz protected Lan 7 (Scheme 4).[28] This 
latter compound was obtained from (R)-6 and -chloroalanine (S)-5. After reaction with 1 M KOH at rt for 3 h, crystallization 




Scheme 4. Diastereoselective synthesis of CBz-Lan. i) (R)-6 (9.2 mmol, 1.47 eq), (S)-5 (6.25 mmol, 1 eq), KOH (1.8 M, 45 mmol), 50 °C to rt, 4 h, 
Et2O (to remove excess (R)-6), pH 3.1, recrystallization, 37%; ii) (R)-3 (6 mmol, 2 eq), (S)-8 (3 mmol, 1 eq), KOH (33% aq., 16 mmol), THF, 70 °C, 
Triton B, 5 h, Et2O, pH 2.7, recrystallization, 46-68%; iii) 10 M HCl in AcOH (1/1), 60 °C, 5-15 h, de 97.9-99.9%. 
Furthermore, compound 9 was recovered after reaction of (R)-3 and (S)-8 in a two-phase system with a phase transfer 
catalyst (PTC), in 68% yield. The same reaction was also realized from (R)-3 and (R)-8 to give 10 after recrystallization 
(yield 46%).  
The CBz-protecting groups of 7 and 10 were then removed by hydrolysis with concentrated HCl in AcOH at 60 °C for 5 - 15 
h to yield meso-Lan and (R,R)-Lan, respectively, in high diastereomeric excess (de) (97.9 - 99.9%; yield unknown). The 
racemization study of 1 in HCl (6 M) showed a decrease in the diastereomeric excesses (de) at a temperature >96 °C 
(Table 1). Fortunately, at 60 °C, no racemization was observed.[28-29] 
 
Table 1. Moore and Stein amino-acid analyses after heating acidic 
solutions of (R,R)-Lan 
t (°C) t (h) Acid[a] (R,R)-Lan[b] meso-Lan[b] 
20 - - 100 0 
96 5 a 97.8 2.2 
96 15 a 95 5 
110 6 a 92.1 7.9 
110 24 a 75.8 24.2 
110 48 a 63.2 36.8 
110 72 a 56.7 43.3 
110 168 a 50.4 49.6 
60 5 b 100 0 
96 5 b 98 2 
96 15 b 93.3 6.7 
96 25 b 90.4 9.6 
96 45 b 85.3 14.7 





In order to identify the natural -methyl-lanthionine (-Me-Lan) present in nisin, Wakamiya et al., in 1985, synthesized four 
of the eight possible -Me-Lan diastereomers.[30] The procedure of Photaki et al., starting from (2S,3S)-11 or (2S,3R)-11 
and (R)-5 or (S)-5 was used (Scheme 5). The resulting compounds 12 were chromatographed, crystallized and the CBz 
protecting group removed at rt with HBr in AcOH. Four diastereomeric -Me-Lan 13-16 were thus obtained. The natural 
compound isolated from nisin was thereby identified as the (2S,3S,6R) isomer (13, Scheme 5). 
Scheme 5. Diastereoselective synthesis of four diastereomers of -Me-Lan. i) 11 (2.5 mmol, 1 eq), 5 (2.5 mmol, 1 eq), KOH (3.4 M, 11.5 mmol), 
50 °C (30 min) to rt, 44 h, Et2O (to remove unreacted 11), HP-20 chromatography (50% aq. MeOH), crystallization, 35-53%; ii) 25% HBr in AcOH, 
rt, 2 h, Et2O, pyridine, recrystallization, 87-99%. 
3.3. Synthesis from bis(chloromethyl)sulfide 
In 1943, Kuhn and Quadbeck developed a synthesis of Lan by condensing the sodium salt of phthalimidomalonate 17 with 
bis(chloromethyl)sulfide 18 in xylenes. The product 19 was then crystallized, hydrolysed and decarboxylated to Lan 
(Scheme 6).[31]  
Scheme 6. Synthesis of Lan from bis(chloromethyl)sulfide. i) 17 (260 mmol, 1.34 eq), 18 (194 mmol, 1 eq), xylenes, 140 °C, 4 h, crystallization, 
80%; ii) 19 (22.4 mmol, 1 eq) HCl (32% aq, 75 mL), dioxan, 140 °C, 24 h, NH4OH, recrystallization, 43%. 
Recrystallization of the crude Lan from ammonia afforded a product which, on the basis of the characteristic triangle-like 
crystals and the melting point of the dibenzoyl derivative, was identified as meso-Lan.  
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3.4. Synthesis from dehydroalanine 
In 1947, Schöberl and Wagner reported that the reaction of 20, a Dha derivative, with (R)-3 led to a mixture of (R,R)-Lan 
and meso-Lan (Scheme 7).[32] The Michael addition occurred readily at 100 °C giving 21, which was hydrolysed to 1. 
Although the reaction proceeded in good yield (83%), it suffered from the lack of diastereospecificity due to the planarity 
of 20. Similarly, Belitz synthesized a mixture of four diastereomers of -Me-Lan through the reaction of 
dl-threo-methylcysteine with 20.[33] 
Scheme 7. Synthesis of Lan from a Dha derivative. i) (R)-3 ·HCl (10 mmol, 1 eq), 20 (20 mmol, 2 eq), NaOH (1 M, 28 mmol, pH 7-8), 50 °C to 
100 °C, 70 min; ii) 21, HCl (20% aq, 300 mmol), reflux, 4.5 h, AcONa, recrystallization, 83%. 
This particular approach was also used for the radioactive syntheses of [35S]Lan. In 1966, rac-[35S]Cys, diluted eleven 
times with enantiomerically pure (R)-3, was used by Gansser.[34] Reaction with 20, followed by recrystallization of the crude 
product, gave mainly the radioactive meso-1 in 70% yield.[34-35] In 1975, Hanus et al. employed this strategy with undiluted 
rac-[35S]Cys to yield a mixture of all three diastereomers of 1 (73%).[36]  
In 1961, Schöberl prepared -Me-Lan from the azlactone derivative 22 of dehydrobutyrine (Scheme 8).[37] The addition of 
(R)-3 to the double bond of Dhb 22 gave 23 which was directly hydrolysed by refluxing in HCl. Benzoic acid was removed 
and, following addition of pyridine in methanol, the zwitterion of -Me-Lan was isolated. The product was recovered as a 
mixture of at least three diastereomers. The major one was presumably identical with the natural compound isolated from 
subtilin.[38]  
Scheme 8. Synthesis of -Me-Lan from a dehydrobutyrine azlactone derivative. i) (R)-3 (100 mmol, 1 eq), 22 (120 mmol, 1.2 eq), THF/H2O; ii) 23, 
HCl (32% aq, 220 mL), reflux, 6 h, pyridine, recrystallization, 55%. 
In 2011, Aydillo et al. described a diastereoselective Michael addition of protected Cys (R)-24 on chiral Dha 25 and Dhb 













Scheme 9. Diastereoselective synthesis of meso-Lan and -Me-Lan 13. i) 25 (0.13 mmol, 1 eq) or 26 (0.35 mmol, 1 eq), (R)-24 (1.1 eq), DBU (1.1 
eq), THF, -78 °C, 30 min (for 25) or 7 h (for 26), SiO2 chromatography. Yields: 90% (27); 57% (28), de >90%; ii) 27-28, HCl (6 M), reflux, 12 h, 96-
97%. 
In particular, addition of DBU to a solution cooled to -78 °C of (R)-24 and 25 in THF provided after 30 min 27 in 90% yield 
with a de >90%. Hydrolysis of 27 in refluxing HCl for 12 h afforded meso-1. The same reaction using (R)-24 and 26 led to 
28 (57% yield, de >90%) which was in turn hydrolysed to -Me-Lan 13. 
In 2016 the same group presented a new chiral conformationally locked Dha 29 (Scheme 10).[40] The reaction of the 
bicyclic analogue 29 with (R)-24 proceeded at 25 °C, in THF, in less than 5 min. The Michael adduct 30 was obtained with 
high yield (95%). To the best of our knowledge, these chiral dehydroalanines 25 and 29 are the only cases in which Michael 
addition occurs with high stereoselectivities to obtain lanthionines with high de.  
Scheme 10. Diastereoselective synthesis of Lan 1. i) 29 (0.047 mmol, 1 eq), (R)-24 (1.1 eq), NEt3 (2.2 eq), THF, rt, 5 min, SiO2 chromatography. 
Yields: 95% (30), de >90%; ii) 30, HCl (4 M), 40 °C, 16 h (no data available). 
The hydrolysis of the Michael adducts has been optimized with a thiogalactopyranose oxazolidinone.[40] Complete 
hydrolysis occurred at 40 °C with aqueous HCl (4 M) after 16 h. These new reaction conditions are less harsh than the 
reflux used in Scheme 9. However, they have not been applied to the (R,R)-Lan synthesis from adduct 30. This bifunctional 
chiral Dha approach is also potentially applicable for preparation of small peptides incorporating Lan. 
3.5. Synthesis from a trimethylammonium salt 
In 1953, Atkinson et al. reported the synthesis of optically inactive Lan 1 through the reaction of a trimethylammonium 














Scheme 11. Synthesis of Lan from a trimethylammonium salt. i) 31 (50 mmol, 1 eq), Na2S (100 mmol, 2 eq), H2O, 100 °C, 12 h; ii) 32, HCl (100 
mL), 100 °C, 6 h, ammonia, recrystallization, 57%. 
The ammonium salt of the acetamido malonate derivative 31 was heated in water with Na2S until the end of trimethylamine 
evolution. HCl hydrolysis of the ester and acetamide moieties of 32 followed by neutralization with ammonia and 
recrystallization afforded Lan. Attempts to obtain cysteine by substituting potassium hydrosulfide for Na2S led also to the 
recovery of Lan. Thus, the cysteine salt reacted more readily than the acid sulphide. 
In 1967, a similar procedure starting from 31 and homocysteine was used by Lou Snow et al. to prepare a mixture of 
L-cystathionine and D-allocystathionine.[42].  
3.6. Synthesis from cystine 
In 1971, Gleason and Harpp prepared (R,R)-Lan by desulfurization of 33. The reaction proceeded in benzene with 
tris(diethylamino)phosphine (P(NEt2)3) to afford 34 in 96% yield (Scheme 12).[43]  
Scheme 12. Synthesis of (R,R)-Lan by desulfurization of a protected cystine. i) 33 (5 mmol, 1 eq), (Et2N)3P (5.5 mmol, 1.1 eq), benzene, rt, 10 min, 
96%; ii) 34 (3 mmol), dioxane, NaOH (1 M, 27 mmol), 5 °C, 30 min, pH 6, 64%. 
Expedient removal of the trifluoroacetyl protecting group, under mildly basic conditions was achieved with 1 M aq. NaOH 
in dioxane (final NaOH concentration 0.7 M). Indeed, using a stronger concentration (2.4 M NaOH), Lan racemized 
completely in 4 h. The procedure is not suitable for preparation of unsymmetrical disulfide due to the ease of disulfide 
exchange in the reaction conditions. 
3.7. Synthesis from aziridine 
In 1987, Hata and Watanabe investigated in phosphate buffer (pH 8) the reaction of Cys (R)-3 with the unprotected 












Scheme 13. Synthesis of meso-Lan and -Me-Lan 13 from an aziridine derivative. i) (R)-3 (1 mmol, 1 eq), (R)-35 (40 mmol, 40 eq), pH 8, 37 °C, 
20 h, preparative HPLC, yields: 24% (meso-1) + 73% (37); or ii) (R)-3 (1 mmol, 1 eq), (2R,3R)-36 (40 mmol, 40 eq), pH 8, 37 °C, 20 h, preparative 
HPLC, yields: 17% (13) + 63% (38). 
In contrast to the reaction of aziridinecarboxylates bearing an electron withdrawing group on the nitrogen, which form 
-amino acids on opening, compound 35 and 36 afforded predominantly -amino acid derivatives. Thus, reaction of a 
large excess of (R)-3 with (R)-35, at pH 8, provided 24% of meso-1 contaminated with 73% of norlanthionine (nor-Lan) 
37. In the same manner, starting from (R)-3 and (R)-36, -Me-Lan 13 (17% yield) was obtained with 38 (63%). Preparative 
HPLC was required to recover the pure Lan 1 and -Me-Lan 13. 
3.8. Synthesis from serine -lactone 
In 1988, the synthesis of (R,R)-1 through the regioselective ring opening of the -lactone derivative (S)-39 was described 
by Arnold et al. (Scheme 14).[45]  
Scheme 14. Synthesis of (R,R)-Lan from Ser -lactone. i) (R)-3 (3.9 mmol, 3 eq), (S)-39 (1.3 mmol, 1 eq), NaOH (1 M, pH 5-5.5), rt, 40 min, AG50-
X8 (80 mL), gradient HCl (0 to 5 M, 1.5 L), recrystallization (pH 6), 93%. 
A high yield (93%) of (R,R)-1 was obtained by the reaction of Ser -lactone (S)-39 with 3 eq of (R)-3 and slow NaOH 
addition to maintain pH at 5.5. However, this efficient method required the removal of excess (R)-3 by a gradient 
chromatography on an AG50-X8 cation-exchange resin.  
3.9. Synthesis from sulfamidate 
In 2014, Denoël et al. prepared the three pure diastereomers of Lan 1. The syntheses were realized from both enantiomers 
of cyclic sulfamidates derivatives 40-41 with (R)-3 or (S)-3. Moreover using rac--Bn-Cys (rac-42), a diastereomeric 














Scheme 15. Synthesis of Lan 1 and (2R/S,6R)--Bn-Lan 46 from sulfamidates. i) (R)-40 or (S)-40 or (R)-41 or (S)-41 (1 eq.), (R)-3 or (S)-3 or rac-
42 (1 eq.), NaHCO3 or CsHCO3 (3.15 eq.), water, N2, rt, 16 h; ii) HClaq., heat, Dowex 50WX8 or crystallization (pH 6). 
The experiments involving the reaction of both enantiomers of the two water-soluble sulfamidates 40 and 41 with both 
enantiomers of Cys 3 are detailed in Table 2. Lan 1 was obtained after reaction in water at rt and subsequent hydrolysis 
of 43-44 with aqueous HCl at a temperature <70 °C. 
 
Table 2. Preparation of Lan 1 and (2R/S,6R)--Bn-Lan 46 
Sulfamidate Cys Base[a] H3O+[b] de[c] Product 
(S)-40 (R)-3 NaHCO3 a 86 (R,R)-1 
(R)-40 (R)-3 CsHCO3 a 94 meso-1 
(R)-41 (S)-3 NaHCO3 b 88 (S,S)-1 
(R)-41 (S)-3 CsHCO3 b >99 (S,S)-1 
(S)-41 (R)-3 CsHCO3 b >99 (R,R)-1 
(R)-41 (R)-3 CsHCO3 b >99 meso-1 
(S)-41 rac-42 CsHCO3 b n.d. 46 (60%)[d] 
[a] NaHCO3 (0.8 M, 3.15 eq.) or CsHCO3 (1.6 M, 3.15 eq.); [b] a) 5 M HCl aq., 
70 °C, 5 h; b) 2.5 M HCl aq., 50 °C, 30 min; [c] de (%) of the crude product in an 
aliquot of hydrolysed solution; [d] Yield of the crystallized product. Table 
reproduced from Denoël.[46] 
 
The de of Lan 1 was measured by HPLC after derivatization with o-phthaldehyde and N-acetyl-cysteine (OPA/NAc). The 
reaction between the sulfamidates (S)-40 or (R)-40 and (R)-3 in presence of NaHCO3 or CsHCO3 as base, gave the 
corresponding Lan isomers with de of 86% and 94%. Similarly, the Boc-protected sulfamidate (R)-41 with (S)-3 and 
NaHCO3 afforded (S,S)-Lan with a de of 88%. A further optimization of the reaction conditions by use of CsHCO3 (1.6 M) 
led, without any enrichment step, to the three diastereoisomers of Lan with excellent de (>99%) from 41 and Cys 3. 
The substantially higher de observed with CsHCO3 and 41 certainly results of an increase in the SN2 rate versus the rate 
of the side reactions (elimination and Michael addition). In turn, this higher reactivity may be explained by the Boc-
substitution which increase the electrophilicity of sulfamidate 41, the less coordinating nature of the cesium counter-ion 
and the higher concentration achieved with the cesium salt. The products were purified either by chromatography on a 
cation-exchange resin or by crystallization. The isolated yields using Dowex 50WX8 were 95% with a chemical purity of 
95% (de >99%). Sparingly washing the product with water increased the chemical purity to 99% but decreased the yield 
to 70%. Similarly, the use of rac--Bn-Cys (rac-42) and (S)-41 led to a diastereomeric mixture of crystalline 




4. Chemical synthesis of protected lanthionines 
4.1. Generality 
Protected Lan are useful precursors for the synthesis of peptides and various synthetic approaches have been investigated 
to achieve chemoselectivity between the two carboxylic functions and the two amino functions of Lan. Three types of 
protected Lan are described in the literature: protected, orthogonally protected, and mutually orthogonally protected Lan. 
While the first type exhibits no complete selectivity, the orthogonally protected Lan parts can be sequentially removed 
independently from each other. In the third type, mutually orthogonally protected Lan, protecting groups on one Lan can 
be removed independently from the protecting groups of the second Lan. In this section, syntheses of these three types 
of protected Lan from various precursors are presented. 
4.2. Synthesis from -chloroalanine 
In 1979, Photaki et al. reported the preparation of cyclolanthionine 50 from the protected Lan 49 (Scheme 16).[28]  
Scheme 16. Synthesis of a protected Lan derivative. i) 9 (1 eq), MeOH, SOCl2 (2.6 eq), rt, 12 h, 92%; ii) 47 (1 eq), trityl chloride (1.1 eq), NEt3 (1.1 
eq), CHCl3, rt, 12 h, 88%; iii) 48 (1 eq), KOH (1 M, 1.05 eq), acetone, rt, 50 min, 81%. 
Starting from the previously described compound 9 (Scheme 4 and 15), diester 47 was synthesized using thionyl chloride 
in MeOH. The amino group of 47 was protected with a bulky trityl (Tr) group leading to 48. Partial saponification of 48 with 
KOH (1.05 eq) gave 49. However, the author did not provide satisfactory evidence regarding purity of 49 (no NMR, no 
elemental analysis, broad melting point (60 – 75 °C)).  
4.3. Synthesis from cystine 
In 1985, Olsen et al. investigated the synthesis of quinomycin from an orthogonally protected Lan. [47] Because they could 
not reproduce the Photaki saponification step (Scheme 16, step iii) [28] due to lack of selectivity, the synthesis of Lan 56 
and 57 was realized via contraction of the unsymmetrical cystines 54-55 (Scheme 17).[47] However, the contraction via 
Harpp’s desulfurization method (Scheme 12) is known to be problematic for the preparation of unsymmetrical Lan since 

















Scheme 17. Synthesis of orthogonally protected Lan by desulfurization of unsymmetrical cystines. i) (R)-52 (4 mmol, 1 eq) or (R)-53 (1.78 mmol, 1 
eq), 51 (1 eq), P(NEt2)3 (1 eq), benzene, rt, 5 h, MPLC, 55-65%; ii) 54 or 55 (1 eq), P(NEt2)3 (1.1-2.5 eq), benzene, rt, 5-12 h, MPLC, 25-58%. 
A first attempt to get Lan 56 from the thiosulfinate derivative 51 by reaction in benzene with P(NEt2)3 in the presence of 
Cys (R)-52 was disappointing. Even in the presence of an excess of phosphine, only unsymmetrical cystine 54 was 
recovered. Isolation of 54, followed by an additional treatment with P(NEt2)3, led to the subsequent desulfurization into Lan 
56 (25-52% yield after MPLC purification). Using the same approach, 57 was prepared in two steps from 51 and (R)-53 
(58%). 
Another strategy, which involves the desulfurization of a cyclic disulfide, was proposed by Cavelier-Frontin et al. in 1992 
(Scheme 18).[48]  
Scheme 18. Synthesis of protected Lan by desulfurization of a cyclic cystine. i) 58 (1 eq), PhI(OAc)2 (1.1 eq), CH2Cl2, rt, 1 h, 70%; ii) 59 (1 eq), 
P(NEt2)3 (25 eq), DMF, rt, 12 h, 22%; iii) 60 (5 mmol, 1 eq), 0.02 M NaOH, i-PrOH, 99%. 
Two differently protected Cys were coupled into 58 via an ethylene diester bridge. The disulfide linkage was formed by 
treatment of 58 with (diacetoxyiodo)benzene. Concomitant deprotection of the trityl groups occurred. Sulfur extrusion of 
59, without racemization, was done with P(NEt2)3. The large excess of phosphine used resulted in tedious isolation of 60 
(22%). Basic hydrolysis of the diester afforded Lan 61. The final yield is not reported. The main limitation of this approach 
results from the presence of two indistinguishable carboxylic acids.  
It is to be mentioned that such desulfurization approach has also been successfully used in the synthesis of polypeptides. 
Indeed in 1983, this key step was employed by Wakamiya et al. in their seminal paper describing the liquid phase peptide 







4.4. Synthesis from dehydroalanine 
In 1996, Probert et al. reported that the desulfurization method, applied to the synthesis of an orthogonally protected Lan 
for solid phase peptide synthesis (SPPS) proceeds only with poor yields (32-44%).[50] Therefore, the Michael addition of 
(R)-63 to the protected Dha 62, was developed (Scheme 19).  
Scheme 19. Synthesis of an orthogonally protected Lan by Michael addition. i) 62 (2.14 mmol, 1 eq), (R)-63 (2.15 mmol, 1 eq), Cs2CO3 (0.06 mmol, 
cat.), CH3CN, rt, 2 h, 72% (before C18 column). 
Treatment of 62 with (R)-63 in CH3CN and a catalytic amount of Cs2CO3 gave the orthogonally protected Lan 64 as a 
mixture of diastereomers (72% yield). After preparative HPLC purification of (S,R)-64 from (R,R)-64 on a C18 column, the 
allyl or methyl ester of 64 was removed in the presence of the Fmoc group.  
4.5. Synthesis from serine -lactone 
In 1995, the protected Lan 68-70 were synthesized by the Arnold’s method (Scheme 14) modified by Shao et al. (Scheme 
20).[45, 51] The reaction proceeded from Cbz-Ser -lactone (R)-65, in organic solvents and basic conditions, rather than in 
water at pH 5.5. However, in preliminary experiments, the main product of the reaction of (R)-65 with (R)-24 was the 
thioester 71. 
Scheme 20. Synthesis of orthogonally protected Lan using Cbz-Ser -lactone. i) (R)-65 (4.5 mmol, 1.05 eq), (R)-24, (R)-66 or (R)-67 (4.3 mmol, 1 
eq), Cs2CO3 (2.2 mmol), DMF, rt, 4 h. Yields: 50% (68) + 30-40% (71); 78% (69) + 72 (traces); 92% (70) + 73 (traces). 
After optimisation of the reaction conditions, Lan 68 (50%) and thioester 71 (30-40%) were obtained from (R)-65 and (R)-
24 in presence of Cs2CO3 or CsHCO3 in DMF. Further trials with more hindered nucleophiles such as (R)-66 or (R)-67 
gave higher yields of Lan 69 or 70, respectively, and only traces of thioesters 72-73. According to Shao, this increase of 
selectivity results from steric factors, namely restricted access to the carbonyl carbon but not to the -methylene of (R)-
65.[51] However, this route was unsuccessful when Fmoc-(R)-Cys-allyl ester (R)-63 was used instead of (R)-24.[50] 
In 2005, Narayan and VanNieuwenhze prepared the orthogonally protected -Me-Lan 76 by reaction of -Me-Cys 75 with 







Scheme 21. Synthesis of orthogonally protected -Me-Lan using Boc-Ser -lactone. i) (S)-74 (0.71 mmol, 1 eq), 75 (0.71 mmol, 1 eq), Cs2CO3 (1 
eq), DMF, rt, 4 h, 52% (76) + 20% (Dhb 77, pathway b). 
NMR characterization demonstrated that this approach gave a single isomer of 76 (52%, pathway a). However, a side 
reaction led to 20% of Dhb 77, presumably through the competing opening of the lactone at the carbonyl group followed 
by a -elimination of the resulting thioester (pathway b, Scheme 21).  
In 2003, Goodman and Smith reported the preparation of orthogonally protected -Me-Lan 84-87, by reaction of Cys 80-83 
with Boc -Me-Ser -lactone (R)-79 (Scheme 22).[53]  
Scheme 22. Synthesis of orthogonally protected -Me-Lan using Boc -Me-Ser -lactone. i) (R)-79 (0.12 mmol, 1 eq), 80-83 (0.15 mmol, 1.25 eq), 
Cs2CO3 (1.25 eq), CH3CN, rt. Yields: 76-83% (84) + 17-24% (88); 78% (85); 99% (86); 80% (87). 
Since no reaction occurred between a cesium thiolate and mesylate (R)-78, the preparation of the Boc -Me-Ser -lactone 
(R)-79 was effected (Scheme 22). In contrast, this lactone (R)-79 and the protected Cys (R)-80 reacted in CH3CN with 
Cs2CO3 to give the orthogonally protected -Me-Lan 84 (76% yield). This was contaminated with the thioester by-product 
88 (24%). The increased bulkiness of Fmoc-protected (R)-81 led to 85 (78%) without any thioester formation. In that case, 
some Fmoc cleavage occurred, slightly decreasing the yield. More hindered nucleophiles such as 82-83 gave Lan 86-87 
as sole products in good yield (80-99%). 
4.6. Synthesis from aziridine 
In 1983, Nakajima et al. prepared the protected Lan 92 and 94 as well as the -Me-Lan 93 and 95 through aziridine 






Scheme 23. Synthesis of protected Lan and -Me-Lan using aziridine. i) (S)-89 or (S,S)-90 (1 mmol, 1 eq), (R)-91 (1 mmol, 1 eq), BF3.Et2O (3 
drops), CH2Cl2, rt, 120 h. Yields: 37% (92); 22% (93); using (R)-89 or (R,R)-90: 21% (94); 12% (95). 
Treatment at rt, for five days, of a mixture of (S)-89 or (S,S)-90 with (R)-91 in CH2Cl2 containing BF3.Et2O, afforded 92 
(37%) or 93 (22%), respectively. Likewise, 94 and 95 were synthesized from (R)-89 or (R,R)-90 with (R)-91, in yield of 
21% and 12%, respectively. The low yields were the major drawback of this method. 
In 2011, the two mutually orthogonally protected -Me-Lan 99 and 101 were used by Liu et al. to prepare both components 
of lacticin 3147 (Scheme 24).[55] 
Scheme 24. Synthesis of mutually orthogonally protected -Me-Lan using aziridine. i) (R,R)-96 (24 mmol, 1 eq), (S)-98 (24 mmol, 1 eq), BF3.Et2O 
(4 eq), CH2Cl2, 4 °C, 72 h, 46% (99); or ii) (R,R)-97 (2.8 mmol, 1 eq), (S)-98 (11 mmol, 4 eq), BF3.Et2O (8 eq), CH2Cl2, rt, 48 h, 40% (100); iii) 100 
(0.12 mmol, 1 eq), thioglycolic acid (0.14 mmol, 1.2 eq), DiPEA (6 eq), Alloc-Cl (1.5 eq), 0°C  rt, 2+24 h, 47%. 
The aziridine route was selected because of its good stereochemical control. To protect the aziridine nitrogen of (R,R)-96, 
a p-nitrobenzyloxycarbonyl (pNZ) group was selected and for the carboxylic acid a p-nitrobenzyl (pNB). After reaction with 
(S)-98 in CH2Cl2, in presence of 4-8 eq of BF3.Et2O, -Me-Lan 99 was recovered in 46% yield. The mutually orthogonally 
protected -Me-Lan 101 containing an Alloc and allyl functions was also prepared. For the synthesis of -Me-Lan 101, the 
starting aziridine (R,R)-97 was modified with a dinitrobenzenesulfonyl (DNs) and an allyl groups. Coupling with (S)-98 
affords 100 in 40% yield. The DNs group was then removed in basic media with thioglycolic acid and the amino group was 
protected again in one pot with Alloc-Cl to give 101 (47%). The expanded structures of the -Me-Lan 99-101 are illustrated 
in Figure 3. An example of application of the mutually orthogonally protected Lan 99 and 101 in the SPPS of an analogue 














Figure 3. Orthogonally protected -Me-Lan 100 and mutually orthogonally protected -Me-Lan 99 and 101. 
4.7. Synthesis from serine 
In 2002 and 2003 Swali et al. and Mohd Mustapa et al. independently investigated the synthesis of protected Lan 104 
through a Mitsunobu reaction.[56] For this reaction, the low reactivity of the thiol was increased by using a mixture of PMe3 
and 1,1′-(azodicarbonyl)dipiperidine (ADDP) (Scheme 25). 
Scheme 25. Synthesis of a protected Lan by a modified Mitsunobu reaction. i) (R)-102 (0.25 mmol, 1 eq), (R)-103 (0.25 mmol, 1 eq), ADDP (2 eq), 
PMe3 (2 eq), Zn tartrate (0.2 eq), CHCl3, rt, 168 h, 52%. 
Unfortunately, those groups reported that no reaction occur with (R)-103. However, Mohd Mustapa et al. demonstrated 
that the addition of a catalytic amount of zinc tartrate resulted in enhanced kinetic and yield of this sluggish reaction. Thus, 
when (R)-102, pre-treated with ADDP and PMe3, was added to a mixture of (R)-103 and zinc tartrate in CHCl3, the 
protected Lan 104 was obtained in 52% yield after seven days at rt.  
4.8. Synthesis from -iodoalanine 
In 1997, Dugave and Ménez described the preparation of the orthogonally protected Lan 108 using the trityl -iodoalanine 




Scheme 26. Synthesis of orthogonally protected Lan using trityl -iodoalanine. i) (R)-105 (1 mmol, 1 eq), (R)-103 (1 mmol, 1 eq), Cs2CO3 (1 eq), 
DMF, rt, 4 h, 88% (106) + 8% (107); ii) 106 (0.5 mmol, 1 eq), TFA (50% in CH2Cl2, 20 mL), rt, 30 min, evaporation, NEt3, Boc2O (1 eq), rt, 12 h, 94%. 
Reaction of (R)-103 with (R)-105 and Cs2CO3 in DMF at rt yielded Lan 106 (88%) and aziridine (S)-107 (8%). Acidolysis 
of the tert-butyl ester and trityl groups of 106 with TFA followed by Boc protection of the free amine gave orthogonally 
protected Lan 108 (94%). For this synthesis, trityl -iodoalanine (R)-105 was previously prepared by reaction of the 
corresponding mesylate with a 10 molar excess of NaI in acetone.[58] Compound (R)-105 was described as a 2:1 mixture 
of rotamers that did not coalesce on heating but were instead converted into the aziridine (S)-107. The optical activity of 
this particular (R)-105 was [𝛼]𝐷
20 = +5° (c 1, CHCl3).[58] Furthermore, Lan 106 was also described as a mixture of 
rotamers.[57] 
In 2002, the method of Dugave and Ménez was modified by Rew et al. while preparing a peptide containing a Lan by 
SPPS.[59] In this case, (R)-105 was synthesized in 93% yield by the Garegg iodination (PPh3/I2/imidazole) of (S)-Tr-Ser-
OBn. The optical rotation of this batch of (R)-105 was [𝛼]𝐷
20 = +14.7° (c 0.37, CHCl3),[59] which is considerably higher than 
the value reported by Dugave and Ménez for the same compound.[58] 
The same year, the method of Dugave and Ménez (Scheme 26) was also adapted by Swali and coworkers for the SPPS 
of orthogonally protected Lan (Scheme 27).[56a]  
Scheme 27. Synthesis of orthogonally protected Lan using trityl -iodoalanine. i) (S)-109 (1 mmol, 1 eq), (R)-103 (1 mmol, 1 eq), Cs2CO3 (1 eq), 
DMF, rt, 4 h, 74% (104) + 16% (110); ii) 104 (2.7 mmol, 1 eq), TFA (50% in CH2Cl2 with 2% TIS, 10 mL), rt, 1 h, evaporation, DiPEA, Boc2O (1 eq), 
rt, 12 h, 62%. 
For this application, a Fmoc strategy and an orthogonal allyl ester protecting group were chosen. Reaction of -iodoalanine 
(S)-109 with (R)-103 and Cs2CO3 in DMF afforded Lan 104 (74%) contaminated with aziridine (R)-110 (16%). The -
iodoalanine (S)-109 was previously prepared by the Garegg iodination of (R)-102 in 84% yield as a 2:1 mixture of rotamers 
that degraded to aziridine (R)-110 upon heating. Furthermore, the 13C NMR of Lan 104 shows dedoubled peaks for the 
tert-butyl, both -methylene carbons, both -carbons and the three allylic carbons. Acidolysis of the trityl and tert-butyl 
groups followed by Boc protection provided 111 (62%). 
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In 2002 and 2003, Mohd Mustapa et al. demonstrated that the interpretations made by Dugave and Ménez and by Swali 
et al. of the reactions of (R)-103 with (R)-105 or (S)-109 had to be reassessed (Scheme 26 and Scheme 27).[56b, 60] Indeed, 
when the synthesis of -iodoalanine 109 is done through the mesylate with the Dugave’s iodination method, 2D-NMR 
shows a mixture with an isomeric form.[58] 
Furthermore, additional 2D-NMR information obtained on the product isolated after the reaction of (S)-109 with (R)-103 
confirms these results (Scheme 28).  
Scheme 28. Synthesis of orthogonally protected Lan and nor-Lan using trityl -iodoalanine. i) (S)-109 (16 mmol, 1.14 eq), (R)-103 (14 mmol, 1 eq), 
Cs2CO3 (1 eq), DMF, rt, 4 h. Yields: 15% (104) + 75% (115); ii) mixture of 104+115 (4.6 mmol, 1 eq), TFA (5% in CHCl3, 27 mL, 4 eq), rt, 4 h; iii) 
mixture of 112+ isomer, Alloc-OSu (9.2 mmol, 2 eq), NaHCO3 (5%, 30 mL), dioxane, 5 °C, 18 h. Yields: 14% (113), 73% (116); iii) mixture of 113+116 
(3.4 mmol, 1 eq), TFA (50% in CHCl3, 10 mL), 4 h, rt, chromatography. Yields: 0% (114), 76% (117). 
The 1H NMR of the crude protected Lan shows two sets of peaks in a 4:1 ratio. Moreover, the HMBC-NMR correlations 
between the methylene protons of the Fmoc part of Lan and the CH next to the allyl carboxylate (trityl part) confirmed that 
nor-Lan 115 (major product) was obtained instead of the two rotamers of 104. Noteworthy, Lan 104 (minor product) was 
a pure diastereomer while nor-Lan 115 was a mixture of diastereomers.[56b, 60] In the next step, the substitution of Alloc for 
trityl on the crude mixture of 104 and 115 was followed by HPLC separation of the isomers 113 and 116. Noteworthy, the 
complete NMR characterization of the purified 113 and 116 confirms the absence of rotamers. 
Moreover, Mohd Mustapa et al. described that the HSQC spectrum of the -iodoalanine prepared from the mesylate 
(R)-118 corresponds to a mixture of enantiomers of -iodo--alanine (R/S)-119, contaminated by the desired -iodo--

























Scheme 29. Mechanism for transformation of Ser mesylate to trityl--iodoalanine using Dugave’s method. Conditions: (R)-118 (46 mmol, 1 eq), NaI 
(10 eq), acetone, rt, 72 h. Yields: 15% [(S)-109]; 72% [(R/S)-119]. 
The same authors reported the mechanism of formation of (S)-109, (R)-110 and (R/S)-119 from mesylate (R)-118.[56b] 
Briefly, during the reaction of mesylate (R)-118 with NaI (10 eq, acetone, rt) aziridine (R)-110 was formed. Subsequent 
ring-opening of (R)-110 with NaI occurred either in the -position (major) or in the -position (minor) giving (S)-119 or (S)-
109, respectively. (S)-109 can also be obtained by direct SN2 reaction of NaI on the mesylate (R)-118. The excess of 
iodide reacted also on the -iodo--alanine (S)-119 to afford (R)-119 through Walden inversion.  
To evaluate the reactivity of the aziridine (R)-110, the authors mixed (R)-110 with Cys (R)-103, Cs2CO3 and DMF 
(conditions described for the formation of Lan 104 from -iodoalanine resulting in 75% of 115, Scheme 28). In this case, 
no reaction at all was observed. Therefore, nor-Lan 115 results from SN2 reaction on the major -iodoalanine regioisomer 
(R/S)-119, while Lan 104 was the product from the minor isomer (S)-109 (Scheme 28 and Scheme 29).  
Removal of the tert-butyl esters of the 1:6 mixture of the two isomers 113 and 116 afforded, after reverse phase 
chromatography, pure nor-Lan 117 (76%, Scheme 28).[56b] From 117, a cyclic peptide containing nor-Lan was prepared in 
Fmoc-based SPPS.[61] 
In Scheme 29, the electron donating trityl group of (R)-118 promotes aziridine (R)-110 formation. In 2005, Bregant et al. 
circumvented this problem by preparing the protected Lan 113 from the carbamate-protected -iodoalanine (S)-120 
(Scheme 30).[62]  
Scheme 30. Synthesis of protected Lan using carbamate-protected -iodoalanine. i) (S)-120 (0.12 mmol, 1.1 eq), (R)-103 (0.11 mmol, 1 eq), Cs2CO3 
(1 eq), DMF, rt, 3 h. Yields: 74% (113) + 13% (121), de: 70%. 
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The reaction of Alloc -iodoalanine (S)-120 with (R)-103 led to the formation of Lan 113 in good yield (74%). However, the 
diastereomer by-product 121 (13%) was also present. Indeed, when -iodoalanine (S)-120 is generated from the mesylate 
and NaI, (S)-120 contains the corresponding elimination by-product Dha 122. The -iodoalanine (S)-120 was thus purified 
by chromatography and used directly because of its instability. However, under the basic reaction conditions, -elimination 
led again to in situ formation of Dha 122. Subsequent reaction of (R)-103 with Dha, gave a 1:1 mixture of 113 and 121. In 
fine, 15% of 121 were present in the final product (de 70%). This diastereomer 121 could not be avoided despite several 
attempts with other reaction solvents or bases. 
This problem prompted Bregant and Tabor to reinvestigate the synthesis of the trityl protected -iodoalanine (S)-109.[62] 
This new approach, developed to minimize the formation of aziridine (R)-110 as well as its conversion into -iodo--alanine 
(R/S)-119 (Scheme 29), implies the reaction between protected Ser (R)-102 and iodomethane (Scheme 31).  
Scheme 31. Regioselective preparation of trityl -iodoalanine. i) (R)-102 (4 mmol, 1 eq), PPh3 (1.5 eq), DEAD (1.5 eq), CH3I (1.5 eq), CH2Cl2, -2 °C, 
3 h. Yields: 72% (109); (R)-110 (traces). 
Reaction at -2 °C of (R)-102 with CH3I in the presence of PPh3 and diethylazodicarboxylate (DEAD), led to (S)-109 with 
only traces of aziridine (S)-110. Moreover, the formation of -iodo--alanine (R/S)-119 was not observed. Orthogonally 
protected Lan 114 was then synthesized from -iodoalanine (S)-109 and (R)-103 according to the route previously reported 
(Scheme 28). From this batch of (S)-109, only Lan 114 was obtained and nor-Lan 117 was not observed.[62] These results 
contrast with those of Mohd Mustapa et al. who obtained as the major product nor-Lan 117.[56b] Lan 114 was then 
incorporated into an analogue of nisin ring C by SPPS synthesis.[62] 
In 2011, SPPS was also used by Mothia et al. to prepare an analogue of rings D and E of the lantibiotic nisin. [63] Since 
these two rings are constituted of overlapping thioether bridges, the synthesis of the mutually orthogonally protected Lan 
114 and 128 was considered (Scheme 32 and Figure 4). 
Scheme 32. Synthesis of protected Lan using trityl -iodoalanine. i) (S)-123 (0.16 mmol, 1 eq), (R)-124 (0.16 mmol, 1 eq), Cs2CO3 (1 eq), DMF, rt, 
4 h, 58%; ii) 125 (0.11 mmol, 1 eq), TFA (10% in CH2Cl2 with 5% TES, 4 mL), rt, 24 h; iii) 126 (0.11 mmol, 1 eq), Teoc-OSu (5 eq), DMAP (1 eq), rt, 














Figure 4. Structure of mutually orthogonally protected Lan 114 and 128 as well as protected nor-Lan 117. 
For the preparation of Lan 128, the trimethylsilylethyl (TMSE) and the -(trimethylsilyl)ethoxycarbonyl (Teoc) protecting 
groups were selected. Indeed, their removal by tetra-n-butylammonium fluoride (TBAF) is orthogonal to Alloc/allyl as well 
as to the transient Fmoc and permanent Boc/t-Bu groups. -iodoalanine (S)-123 was prepared by the Mitsunobu reaction 
with iodomethane as described above (Scheme 31). Coupling of (S)-123, in DMF, with (R)-124 in the presence of Cs2CO3 
gave the orthogonally protected Lan 125 (58%). After trityl removal and subsequent protection of the amine of 126 with a 
Teoc, 127 was obtained in 66% yield (two steps). The trichloroethyl ester (Tce) was removed in neutral conditions with Zn 
and ammonium acetate to provide Lan 128. Synthesis of the bicyclic peptide analogue of rings D and E of nisin was then 
successfully accomplished. 
The expanded structures of Lan 114, nor-Lan 117 and Lan 128 are illustrated in Figure 4.  
4.9. Synthesis from -bromoalanine 



















Scheme 33. Synthesis of orthogonally protected Lan using -bromoalanine. i) (R)-129 (0.21 mmol, 1.05 eq), (R)-130 (0.2 mmol, 1 eq), NaHCO3 (3 
mL, pH 8.5), TBAHS (4 eq), EtOAc, rt, 12 h, 92%; ii) (S)-132 (0.21 mmol, 1.05 eq), (R)-63 (0.2 mmol, 1 eq), NaHCO3 (3 mL, pH 8.5), TBAHS (4 eq), 
EtOAc, rt, 12 h, 84%; iii) 133 (0.095 mmol, 1 eq), N-methylaniline (3 eq), Pd(PPh3)4 (1.05 eq), THF, rt, 1 h, 94%. 
The reaction of (R)-129 with (R)-130, performed in a biphasic mixture of aqueous NaHCO3 and EtOAc with tetra-n-
butylammonium hydrogensulfate (TBAHS) as PTC, afforded the orthogonally protected Lan 131 in 92% yield. The same 
reaction with (S)-132 and (R)-63 led to 133 (84%). The Lan 131 and 133 were diastereoselectively pure and did not contain 
any nor-Lan. Treatment of 133 with Pd(PPh3)4 and N-methylaniline gave Lan 134 (94%). 
In 2006, the four Lan diastereoisomers 135-138 were independently synthesized by Seyberth et al. by reacting (R)-129 
and (S)-129 with Cys (R)-63 and (S)-63 (Scheme 34).[65]  
Scheme 34. Synthesis of protected Lan using -bromoalanine. i) (R)-129 or (S)-129 (1 mmol, 1.1 eq), (R)-63 or (S)-63 (0.91 mmol, 1 eq), DiPEA 
(5% in DMF, 8 mL), rt, 4 h. Yields: 65% (135), 62% (136), 58% (137), 56% (138). 
The four couplings proceeded with diisopropylethylamine (DiPEA, 5%) in DMF with an average yield of 60%. As shown 
by 2D-NMR, the carbamate protection avoided the formation of nor-Lan, but the product was contaminated by a small 
27 
 
amount of Dha.[65] This absence of nor-Lan results from the absence of -halo--alanine (Scheme 29). This reactant 
cannot occur because the aziridine formation from -haloalanine is inhibited by the carbamate protection of the amino 
group which prevents the intramolecular cyclisation.[62] The diastereomeric purities of 135-138 were determined by chiral 











In 2008, Martin developed a synthesis of alternative Lan building blocks suitable for SPPS, with the amine protected with 
an isovaleryldimedone (ivDde) group.[67]. The protected Cys (R)-103 was coupled with the mesylate (R)-139 by using the 
biphasic Zhu conditions (NaHCO3/EtOAc).[64] Unfortunately, this approach led to a mixture of diastereomers of Lan 140 
with unsatisfactory de due to elimination of (R)-139 to Dha during the synthesis (Scheme 35).  
Scheme 35. Synthesis of protected Lan using a mesylate. i) (R)-103 (3.1 mmol, 1.1 eq), (R)-139 (2.8 mmol, 1 eq), NaHCO3 (5 mL, 1.5 eq), TBAB 
(0.5 eq), EtOAc, rt, 6 h, 92%. 
Therefore, the position of the protecting groups on the starting substrates was switched and Lan 142 was synthesized 
through PTC coupling of -bromoalanine (R)-129 and Cys (S)-141 (52%, Scheme 36). The fair yield results from a 
competing degradation of (S)-141, presumably due to the allyl group. The synthesis was further investigated with a TMSE 
ester protection (144). The reaction of (R)-143 with (S)-144 afforded a single diastereomer of Lan 145 in a higher yield 
(88%). Removal of the allyl ester of 145 with Pd(PPh3)4 (5 mol%) and N-methylaniline led to 146 in 87% yield. The structure 
of the protected Lan 146 is shown in Figure 5. 
Scheme 36. Synthesis of protected Lan using -bromoalanine. i) (R)-129 (1.54 mmol, 1.1 eq), (S)-141 (1.4 mmol, 1 eq), NaHCO3 (saturated, pH 
8.5), TBAB (4 eq), EtOAc, rt, 14 h, 52% (142); or ii) (R)-143 (7.2 mmol, 1.1 eq), (S)-144 (6.5 mmol, 1 eq), NaHCO3 (saturated, pH 8.5), TBAB (4 eq), 






Table 3. Diastereomeric purities (%) of Lan 135-138[a] 




135 (2R, 6R) 97.3 2.7 0 
136 (2R, 6S) 1.3 97.1 1.6 
137 (2S, 6R) 2.6 96.7 0.7 
138 (2S, 6S) 0.1 4.1 95.8 
[a] Chiral GC-MS according to Küsters.[66] Analysis on a Chirasil-Val column 
after derivatization to the N,N’-bis-(trifluoroacetyl)-Lan--allyl--methyl diester. 




Figure 5. Detailed representation of protected Lan 146, -Me-Lan 149 and nor-Lan 159. 
In 2005, the method of Zhu[64] was also used by Narayan and VanNieuwenhze to prepare the orthogonally protected 
-Me-Lan 147.[52] After reaction of -Me-Cys 75 with -bromoalanine (R)-132, the -Me-Lan 147 and the by-product Dha 
148 were recovered in 60% and 21% yield, respectively (Scheme 37).  
Scheme 37. Synthesis of orthogonally protected -Me-Lan using -bromoalanine. i) Zhu conditions: (R)-132 (0.34 mmol, 1 eq), 75 (0.34 mmol, 
1 eq), NaHCO3 (saturated, pH 8.5), TBAHS (4 eq), EtOAc, rt, 12 h. Yields: 60% (147) + 21% (148); or ii) Narayan conditions: (R)-132 (0.34 mmol, 1 
eq), 75 (0.34 mmol, 1 eq), Cs2CO3 (saturated, pH 12), TBAHS (4 eq), EtOAc, rt, 12 h. Yields: 72% (147) + 13% (148). 
By substituting Cs2CO3 (pH 12) for NaHCO3 (pH 8.5) the yield of 147 increased to 72% and 148 was formed in 13% yield. 
In 1H and 13C NMR, small peaks that did not disappear on heating seem to indicate that diastereomers are presents. In 
the paper, no de value of 147 is reported. 
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In 2012, a liquid phase peptide synthesis approach was used by Carillo and VanNieuwenhze to synthesize the D-ring of 
Mersacidin. For this work, the orthogonally protected -Me-Lan 150 was prepared in two steps according to Scheme 38.[68]  
Scheme 38. Synthesis of orthogonally protected -Me-Lan using -bromoalanine. i) (R)-129 (22 mmol, 1 eq), 75 (22 mmol, 1 eq), Cs2CO3 (220 mL, 
pH 13), TBAHS (4 eq), EtOAc, rt, 12 h, 65%; ii) 149 (0.77 mmol, 1 eq), Me3SnOH (6 eq), ClCH2CH2Cl, 78 °C, 4 h, 70%. 
The PTC methodology of Zhu (TBAHS and a biphasic mixture of EtOAc/water)[64] and the alkaline conditions of Narayan 
(Cs2CO3)[52] applied to (R)-129 and 75 afforded the -Me-Lan 149 in 60% yield. The methyl ester of -Me-Lan 149 was 
selectively removed by reflux in dichloroethane with Me3SnOH to give the orthogonally protected -Me-Lan 150 (70% 
yield). 
In 2008, bis(desmethyl) lacticin 3147 A2, an analogue of that lacticin with two Lan substituted for -Me-Lan, was 
synthesized in SPPS by Pattabiraman et al.[69] This synthesis requires the protected Lan 113 previously prepared by Zhu 
PTC conditions from (S)-151 and Cys (R)-103 (Scheme 39).[64] 
Scheme 39. Synthesis of protected Lan using -bromoalanine. i) (S)-151 (6.9 mmol, 1 eq), (R)-103 (6.9 mmol, 1 eq), NaHCO3 (0.5 M, pH 8.5), TBAB 
(4 eq), EtOAc, rt, 24 h, 73%. Yields: 66% (113) + 7% (121), de: 81%. 
Even if the pH of the reaction never exceeded 8.5 (NaHCO3, rt, 24h), 13C NMR analysis of the product shows the presence 
of the diastereomer 121 and a de of 80% was then extrapolated.[69] The same two Lan 113 and 121 had been previously 
prepared by Bregant and Tabor from -iodoalanine (S)-120 (de of 70%, cf. Scheme 30).[62] These syntheses of Lan from 
carbamate-protected bromo or -iodoalanine afford a mixture of diastereoisomers resulting from side reactions with Dha 
122. From this 80% de Lan 113, a Fmoc-based SPPS strategy gave the target lacticin 3147 A2 analogue (1.3% global 
yield after 22 coupling reactions and three cyclisations).[69]  
In 2012, Knerr and van der Donk described the preparation of epilancin 15X analogues. [70] This lantibiotic contains three 
rings, one with Lan and two with -Me-Lan. Since two of those rings are constituted of overlapping thioether bridges, the 
two mutually orthogonally protected -Me-Lan 99 and 101 were synthesized in two steps from -Me-Cys 152 and (R)-129 
(Scheme 40). Those same protected Lan 99 and 101 were also prepared in 2011 via an aziridine pathway by the Vederas 















Scheme 40. Synthesis of mutually orthogonally protected -Me-Lan using -bromoalanine. i) (R)-129 (1 mmol, 1 eq), 152 or 153 (1.5 mmol, 1.5 eq), 
NaHCO3 (0.5 M, pH 8.5), TBAB (4 eq), EtOAc, PBu3 (0.5 eq), rt, 24 h. Yields: 64% (154), 85% (155); ii) 154 or 155 (0.8 mmol, 1 eq), TFA (50% in 
CH2Cl2 with 1.05 eq PhSiH3, 6 mL), rt, 2 h, 95% (101), 95% (99). 
Using the Zhu conditions,[64] modified by the addition of PBu3, the -Me-Lan 154 is recovered in 64% yield. TFA acidolysis 
of 154 in the presence of PhSiH3 removed the tert-butyl ester to give the -Me-Lan 101 (95%). The same conditions 
applied to -Me-Cys 153 and (R)-129 afforded 155 (85% yield), which after TFA acidolysis affords the -Me-Lan 99 in 95% 
yield. Noteworthy, preparation of 154 from a -Me--bromoalanine resulted in low yields and partial epimerization. 
Subsequent SPPS led to the epilancin 15X analogues in 1.6-1.9% yield (92-93% average per step). The diastereomeric 
purities of Lan and of -Me-Lan in the peptides were determined by chiral GC-MS on a Chirasil-Val column after 
derivatization of the hydrolysate (HCl 6 M, 100 °C, 20 h) of each synthetic epilancin analogue. The incorporated meso-Lan 
contained small amounts of (R,R)-Lan and (S,S)-Lan probably due to epimerization during the hydrolysis step. However, 
the incorporated -Me-Lan exhibited excellent diastereomeric purity.  
4.10. Synthesis from sulfamidate 
In 2006, Avenoza et al. prepared an orthogonally protected -Me-nor-Lan from a -amino acid sulfamidate derivative 
(R)-156 (Scheme 41).[71] 
Scheme 41. Synthesis of orthogonally protected -Me-nor -Lan using sulfamidate. i) (R)-156 (0.15 mmol, 1 eq), (R)-157 (0.17 mmol, 1.1 eq), DBU 
(1.05 eq), DMF, 50 °C, 1 h; ii) H2SO4 (20% aq), CH2Cl2, rt, 10 h, 91%. 
Reaction of (R)-156 with (R)-157 and DBU in DMF at 50 °C for 1 h gave the intermediate sulfamate 158. Strikingly, the 
nucleophilic attack occurred on the tertiary substituted carbon. Hydrolysis of 158 in a biphasic mixture of 20% H2SO4 and 












In 2007, the preparation of Lan and -Me-Lan derivatives from cyclic sulfamidates was investigated by Cobb and Vederas 
(Scheme 42).[72] 
Scheme 42. Synthesis of protected Lan and -Me-Lan using sulfamidates. i) 160 (0.6 mmol, 1 eq) or 161 (0.54 mmol, 1 eq), (R)-52 (1.2 eq), Cs2CO3 
(1.2 eq), DMF, rt, 20 h, evaporation; ii) 162 or 163, BF3.Et2O (1.5 eq), n-PrSH (1.5 eq), CH2Cl2, 0 °C, 16 h. Yields: 89% (164), 70% (165). 
The sulfamidates 160 and 161 were prepared from para-methoxybenzyl (PMB) protected Ser and allo-Thr methyl ester, 
respectively. Reaction of 160 with (R)-52 and Cs2CO3 in DMF afforded the intermediate sulfamate 162 whose hydrolysis 
at rt with NaH2PO4 (1 M, pH 5.4) was not complete after 24 h (40%). An alternative method with BF3.Et2O and n-PrSH in 
CH2Cl2 led to Lan 164 in 89% yield. When the reaction is conducted using the more hindered sulfamidate 161 and (R)-52, 
-Me-Lan 165 is recovered in good yield (70%). The use of the Fmoc protected Cys (R)-103 instead of (R)-52 gave side 
products due to the low stability of the Fmoc group in the presence of Cs2CO3. The de of 164-165 was >90%, as shown 
by the absence of other diastereomers in 13C NMR. The main limitation of this powerful method concerns the preparation 
of the starting sulfamidates that needs oxidative conditions unsuitable for the allyl and Alloc protecting groups. 
In 2014, Denoël et al. prepared five protected -alkyl-Lan 171-175 from 4-alkylated cyclic sulfamidates (Scheme 43).[73]  
Scheme 43. Synthesis of protected -alkyl-Lan using sulfamidates. i) 166-169 (1 mmol, 1 eq), (R)-24 (1.1 mmol, 1.1 eq), DBU (1.1 eq), CH3CN, rt, 
1 h; ii) 10% aq. NaH2PO4, EtOAc, 50 °C, 2 h, 90-99%; iii) 173 (0.54 mmol), H2 (7 bars), Pd black (25% w/w), 9:1:0.3 (MeOH/H2O/AcOH), 70 °C, 
16 h, 73%. 
The reaction between N-Benzyl protected sulfamidates 166-169 and Cys (R)-24 proceeds with DBU in CH3CN at rt. 
Hydrolysis of the sulfamate function of 170 by heating in 10% aq. NaH2PO4 (50 °C, 2 h) afforded the protected Lan 171-174 
(90-99%). It was previously known from the work of Goodman and Smith that the -methylated mesylate (R)-78 was not 
reactive with thiolate derivatives.[53] However, sulfamidates 166-169 display good reactivities with Cys (R)-24 despite the 
sterically crowded -carbon of the -alkylated cyclic sulfamidates.[73] This demonstrates the higher reactivity of cyclic 
sulfamidates versus the linear mesylate. In the last step, the N-debenzylation of 173 in presence of the thioether function 
was found to be challenging. Treatment with Pd black in warm acidic aqueous MeOH overcame this issue and Lan 175 
was obtained in 73% yield.  
The same year, Denoël et al. reported the preparation of the diastereomerically pure protected -benzyl-Lan 180-182 from 






Scheme 44. Synthesis of protected -benzyl-Lan using sulfamidates. i) (R)-176 (0.66 mmol, 1 eq), Boc2O (1 eq), DMAP (10 mol%), NEt3 (cat.), 
CH3CN, rt, 16 h, 93%; ii) (R)-177 (0.24 mmol, 1 eq), (R)-179·HCl (1 eq), DBU (2.3 eq), CH3CN, rt, 1 h; iii) 10% aq. NaH2PO4, EtOAc, 50 °C, 2 h, 
Na2CO3, 78%. 
The sulfamidate (R)-176 was reacted with Boc2O and DMAP to give (R)-177, which has increased electrophilic properties. 
A regioselective opening of (R)-177 with Cys (R)-179, in CH3CN containing DBU at rt, provided the Lan sulfamate 180. 
High selectivity for the thiolate part of (R)-179 was observed without any reaction on the amine. After hydrolysis of the 
sulfamate 180 with 10% aq. NaH2PO4 (50 °C, 2 h), the protected -benzyl-Lan 182 was isolated by chromatography (78%). 
Alternatively, in a one pot process, 180 was directly converted into a protected tripeptide (not shown). The same procedure 
from (R)-178 provided 181 that was converted into a tripeptide (84%). Interestingly, in the conditions described for Boc 
protected (R)-177, no reaction occurred between (R)-176 and (R)-179. This result shows that the substitution of the 
nitrogen atom of the sulfamidates with either a benzyl (Scheme 43) or a carbamate group (Scheme 44) is a prerequisite 
for the reaction of thiolate nucleophiles with -alkylated cyclic sulfamidates. A similar observation was reported by Navo 
et al. in a computational and experimental study of the substituent effects on the reactivity of cyclic tertiary sulfamidates 
derived from α-methylisoserine that strongly depends on the substitution at the C and N termini.[75] 
4.11. Application 
Lan and -Me-Lan are key constituents in lantibiotics, a prevalent class of peptide antibiotics. The development of new 
synthetic routes to the natural lantibiotics or analogues with enhanced properties is the subject of a growing body of 
research.[10, 14] The first total synthesis of a lantibiotic (nisin), in liquid phase, was described by Fukase et al. in 1988.[76] 
Nowadays, the total synthesis of lantibiotics is performed via biosynthetic approaches or chemically using SPPS.[77] This 
last high yielding approach is especially useful for the lengthy multistep protocol of peptide elongation. The preparation of 
the bis(desmethyl) analog of lantibiotic lacticin 3147 A2 using SPPS was described by Pattabiraman et al. in 2008.[69] The 
first total synthesis of a naturally occurring lantibiotic (lactocin S) was reported in 2010.[78] This preparation used the 
orthogonally protected Lan 114 (Figure 4) and the overall purified yield of lactocin S was 10% (71 steps). Lactocin S ring 
analogs with improved stability against oxidation have been similarly synthesized.[11] In 2011, Liu et al. achieved the first 
preparation of -Me-Lan containing lantibiotics lacticin 3147 A1 and A2 using the -Me-Lan 99 and 101 (Figure 3).[55] 
Together with Lan 114, those mutually orthogonally protected -Me-Lan allow the SPPS synthesis of a peptide chain 
containing overlapping lanthionine bridges. Other naturally occurring lanthipeptides such as lacticin 481 and cytolysin were 
similarly prepared.[23, 79] The case of an analogue of epilancin 15X presented hereafter exemplifies the particular challenge 
of building overlapping lanthionines bridges in a peptide and the use of the mutually orthogonally protected Lan 99, 101 
and 114. 
The synthesis of an analogue of epilancin 15X, from the two mutually orthogonally protected -Me-Lan 99 and 101 as well 
as Lan 114, in SPPS was reported by Knerr and van der Donk in 2012.[70] This synthesis began by the loading of 
Fmoc-Lys(Boc)-OH onto a Wang resin (0.10 mmol/g, 400 mg) (Scheme 45). After Fmoc deprotection of Lys with 20% 
piperidine in DMF, a standard Fmoc methodology with N,N’-Diisopropylcarbodiimide (DIC) and 1-hydroxybenzotriazole 
(HOBt) was used to link Fmoc-Lys(Boc)-OH. After Fmoc deprotection, Fmoc-Gly-OH was coupled using the standard 
Fmoc methodology and deprotection. Thereafter, a Dhb-containing dipeptide (2 eq), preactivated with 1-hydroxy-7-
azabenzotriazole (HOAt) and DIC/DiPEA, was added to afford 183. Coupling of Fmoc-His(Tr)-OH by the standard protocol 
was effected. The mutually orthogonally protected -Me-Lan 99 (1.5 eq) was preactivated with HOAt and DIC and added 
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to give 184. Subsequent Fmoc removal and coupling with Fmoc-Gly-OH was realized using the standard procedure. The 
Alloc/allyl protected -Me-Lan 101 (1.5 eq) was preactivated with HOAt and DIC and reacted again with the resin-bound 
peptide to give 185. A 6 M solution of SnCl2 in DMF was used to remove the pNB and pNZ groups. Fmoc deprotection, 
followed by cyclisation using (7-azabenzotriazol-1-yloxy) tripyrrolidinophosphonium hexa fluorophosphate (PyAOP), HOAt 
and 2,4,6-collidine in DMF gave 186 (Scheme 45).  
Scheme 45. SPPS of a peptide fragment of epilancin 15X. i) 183 (0.10 mmol/g on 400 mg Wang resin, from Lys, Lys, Gly, Dhb-Phe dipeptide, 
standard Fmoc method [viz. Fmoc-AA (5 eq), DIC (5 eq), HOBt (5 eq), DMF, 1 h, Kaiser test, MALDI-TOF MS ; Fmoc-deprotection: 20% piperidine 
in DMF, 20 min]), His, 99 (1.5 eq), DIC (3 eq), HOAt (3 eq), 2 h ; ii) 184, Fmoc deprotection, Gly, 101 (1.5 eq), DIC (3 eq), HOAt (3 eq), 2 h ; iii) 185, 
SnCl2 (6 M in DMF, 5 mL), rt, 1 h, repeat (1 x), Fmoc deprotection ; cyclisation step: PyAOP (5 eq), HOAt (5 eq), collidine (10 eq), DMF, 1.5 h ; 
repeat cyclisation step (1 x). 
Fmoc-Leu-OH was coupled on 186 using the standard method but not Fmoc deprotected. The Alloc and allyl groups were 
removed using Pd(PPh3)4 (1 eq) and PhSiH3 (10 eq) in 1:1 (DMF/CH2Cl2). Subsequent Fmoc removal and cyclisation 
using PyAOP, HOAt and 2,4,6-collidine in DMF gave 187 (Scheme 46). Following the standard method, Fmoc-Phe-OH, 
Fmoc-Gly-OH, and Fmoc-Arg(Pbf)-OH were then added. Lan 114 (1.5 eq) was preactivated with HOAt and DIC and 
reacted with the resin-bound peptide. After Fmoc deprotection, Fmoc-Leu-OH, Fmoc-Lys-(Boc)-OH and another Fmoc-
Lys-(Boc)-OH were added. Allyl/alloc were removed as above followed by cyclisation with PyAOP/HOAt/collidine (188). 
Further coupling steps and N-terminus acylation with (R)-lactic acid and 3-(diethoxyphosphoryloxy)-1,2,3-benzotriazin-
4(3H)-one (DEPBt) afforded, after cleavage and HPLC purification, 2 mg of the epilancin 15X analogue (189) with an 






Scheme 46. SPPS of epilancin 15X analogue 189 from 186. i) 186, Leu, Pd(PPh3)4 (1 eq), PhSiH3 (10 eq), 1:1 (DMF/CH2Cl2), rt, 2 h, Fmoc removal, 
PyAOP (5 eq), HOAt (5 eq), collidine (10 eq), DMF, 2 h, repeat cyclisation (1 x) ; ii) 187, Phe, Gly, Arg, 114, DIC (3 eq), HOAt (3 eq), 2 h, Fmoc-
deprotection, Leu, Lys, Lys, Pd(PPh3)4 (1 eq), PhSiH3 (10 eq), 1:1 (DMF/CH2Cl2), rt, 2 h ; iii) 188, Ala, Lys, Ile, Abu, Abu, Lys, Val, Ile, Ala, Ala, (R)-
lactic acid, DEPBt (5 eq), DiPEA (10 eq), 2 h, 90:5:2.5:2.5 TFA/H2O/triisopropylsilane/thioanisole, 2 h, HPLC. Global yield: 1.6% (189). 
The synthesis of the epilancin 15X analogue (189) and of lacticin 3147 A1 whose structure also contains two overlapping 
-Me-Lan bridges, is challenging. The chemical strategy to prepare such overlapped lanthipeptides implies a mutually 
orthogonal approach and a key deprotection step with the selective removal of either the pNZ/pNB moieties with 
conservation of the Alloc/allyl groups (epilancin) or the reverse way (lacticin 3147 A1).[55, 70] These two examples 
demonstrate the power of this useful method which opens the way to the chemical synthesis of other Lan containing 
polycyclic peptides and analogues through SPPS. 
5. Conclusion 
The discovery of new lantibiotics and analogues with enhanced properties is a hot topic of research. SPPS strategy to 
those peptides, allowing easy modification of the skeleton of lantibiotics, will surely remain a continuing trend for years to 
come. Two amino acids, Lan and -Me-Lan, are key components in lantibiotics. Their regio- and diastereoselective 
preparation is not easy and the characterization of the reaction products was historically subject to numerous errors. With 
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the broadening use of 2D NMR, the interpretation of the products of these syntheses was significantly improved. Since 
2003, most of the newly published syntheses proceed with increased selectivity, leading to reduced side products. 
Depending on the strategy, various side reactions (e.g. racemization, elimination, transposition, hydrolysis) are reported. 
Racemization: most of the unprotected Lan syntheses require acidic hydrolysis or strongly basic conditions. In the standard 
hydrolysis conditions (T >96 °C and pH 0), loss of diastereopurity of Lan is observed (Table 1). Complete racemization of 
Lan, at rt, is also reported in aqueous basic conditions (2.4 M NaOH, 4 h).[43] In most preparation of unprotected Lan, the 
extent of racemization is not well documented since Lan de are usually reported after recrystallization. Milder synthesis 
conditions (pH 8) or hydrolysis temperature (60-70 °C, 5 h) diminish the rate of Lan racemization.[28, 46] 
Elimination: this side reaction occurs in basic medium with amide- and carbamate- protected haloalanines, sulfamidates 
and presumably also with unprotected haloalanines. Synthesis of Lan from these different compounds proceeds either via 
direct SN2, which preserves the stereochemical integrity, or through an elimination-addition pathway. This last route, which 
affords a diastereoisomeric mixture of Lan, involves a planar Dha intermediate formed by -elimination and subsequent 
Michael addition with Cys thiolate. The elimination reaction is also problematic during the synthesis of protected Lan, 
especially with sterically encumbered starting materials. By adjusting the experimental conditions, the SN2 pathway can 
be favoured. As exemplified for sulfamidates, a lower pH (8 vs 12), a less coordinating counter-ion (Cs+ vs Na+), and a 
higher concentration of reactant limits the extent of the elimination (Table 2). [46] Therefore, to avoid this side reaction, we 
propose the use of CsHCO3 instead of the more commonly used NaHCO3 or Cs2CO3 in the biphasic syntheses starting 
from protected bromo alanine derivatives. 
Transposition: depending on the reaction conditions, this isomerisation happens with aziridine derivatives. In aprotic acidic 
conditions, the desired Lan regioisomer is obtained from aziridines protected with an electro-withdrawing group and a 
Cys.[55] However, in an aqueous basic medium, without electro-withdrawing group on the aziridine nitrogen, the main 
product formed is the -substituted -amino acid derivative namely nor-Lan.[44] Another process that also leads to nor-Lan 
involves -iodoalanine trityl derivatives contaminated with the -iodo--alanine isomer. This iodo regioisomer by-product 
is previously generated during the synthesis of trityl -iodo--alanine by reaction of an in-situ formed aziridine with 
iodide.[56b, 60] Reaction of Cys with trityl -iodo--alanine thereby gives nor-Lan derivatives. 
Thioester formation: according to the reaction conditions, thioester formation arises with lactone derivatives. In aqueous 
acidic conditions (pH 5.5), Ser -lactone and Cys afford only Lan.[45] On the other hand, in aprotic basic conditions, Lan is 
contaminated by a thioester by-product resulting from nucleophilic attack of the Cys thiolate on the ester function of the 
lactone derivative. Highly sterically encumbered starting materials typically decrease this side product formation 
(0-40%).[51-53] 
Disulfide exchange: this reaction concerns the synthesis of Lan from cystine derivatives. This approach is optimal with 
symmetrical cystine (96% yield).[43] With unsymmetrical cystine, disulfide exchange readily occurs. This method affords 
sometimes the desired Lan but with fair yield (25-58%).[47]  
Hydrolysis: in aqueous conditions, some electrophilic compounds such as lactones and sulfamidates are prone to 
hydrolysis into the corresponding serine derivatives. Optimization of the reaction parameters (number of Cys equivalents, 
concentration of reactants, pH, temperature) allows to minimize this side reaction. 
Furthermore, even if other reactions seem convenient to realize, reaction kinetic limitations restrict their potential. For 
instance, Mitsunobu reaction, from serine derivatives, is sluggish (52% yield after seven days).[56b] Slow reaction kinetic is 
also observed with -alkylated electrophilic compounds. In this case, sulfamidates or lactones have to be used. [53, 73]  
For the preparation of unprotected Lan, some of the synthetic routes presented in this review are more appropriate than 
others. The method by disulfide reduction of symmetrical cystines is economical and easy to implement for the preparation 
of optically active Lan (R,R and S,S).[43] With commercially available electrophilic precursors (e.g. -chloroalanine, Ser 
-lactone), some of the other approaches described above can be used for meso-Lan.[45] However, due to the lack of 
stereoselectivity (-chloroalanine), recrystallization of the meso-Lan is necessary and further analysis of the de is 
mandatory. Synthesis from lactone provides very good yields. However, the starting material is quite expensive and this 
approach requires an excess of Cys that needs to be eliminated thereafter. Since partial conversion of Cys into cystine 
occurs during the process, whose properties are similar to the Lan to be purified, purification is challenging. Synthesis 
from Dha or Dhb needs a chiral oxazolidinone scaffolds to achieve high diastereoselectivity but a protected cysteine and 
chromatography were used.[32, 39-40] The aziridine in an aqueous alkaline medium gives a product mixture in which nor-Lan 
prevails. Synthesis from sulfamidates is advantageous, the de in presence of CsHCO3 is very high (94-99%) without any 
recrystallization.[46]  
Orthogonally or mutually orthogonally protected Lan and -Me-Lan are useful building block for peptide synthesis, whose 
preparation require the discrimination of the two acid and amine functions on lanthionines.  
For liquid phase peptide synthesis, orthogonally protected lanthionines are most often used. According to the selected 
approach, several Lan protection schemes are possible and the optimal strategy should be selected after pondering the 
main limitations resulting from the side reactions described above. 
For SPPS, the Fmoc strategy with mutually orthogonally protected lanthionines is the most practical approach to prepare 
polypeptides with Lan and -Me-Lan. Particularly suitable compounds are Alloc/allyl protected Lan 114 and -Me-Lan 101. 
When two overlapping bridges are present, those lanthionines can be used in combination with the mutually orthogonally 
protected Lan 128 and -Me-Lan 99. Synthesis of those mutually orthogonally protected lanthionines has been performed 
from aziridine, -bromoalanine or -iodoalanine. This SPPS strategy with mutually orthogonally protected Lan and 
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Layout 1: 
Non-standard amino acid lanthionine, discovered through hydrolysis of wool, is mainly found in the family of cyclic peptide antibiotics called 
lantibiotics. Laboratory preparation of these bioactive compounds displaying interesting properties require efficient lanthionine synthesis. This review 
summarizes the chemical routes to lanthionine from multiple precursors, disclosing the experimental data and analysing the advantage and 
disadvantage of each method. 
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